PHIO (Phio Pharmaceuticals) Float Percentage Of Total Shares Outstanding : 99.87% (As of Apr. 26, 2025)

View and export this data going back to 2012. Start your Free Trial

What is Phio Pharmaceuticals Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Phio Pharmaceuticals's float shares is 4.77 Mil. Phio Pharmaceuticals's total shares outstanding is 4.78 Mil. Phio Pharmaceuticals's float percentage of total shares outstanding is 99.87%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Phio Pharmaceuticals's Insider Ownership is 31.57%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Phio Pharmaceuticals's Institutional Ownership is 3.22%.

Phio Pharmaceuticals Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Phio Pharmaceuticals's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	4.77	/	4.78
	=	99.87%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Phio Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Phio Pharmaceuticals Corp (NAS:PHIO) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

11 Apex Drive, Suite 300A PMB 2006, Marlborough, MA, USA, 01752

Website

https://www.phiopharma.com

Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.

Executives

Robert J Bitterman	director	C/O RXI PHARMACEUTICALS CORPORATION, 1500 WEST PARK DRIVE, SUITE 210, WESTBOROUGH MA 01581
Robert L Ferrara	director	257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Patricia A Bradford	director	UNISYS CORPORATION, 801 LAKEVIEW DRIVE, SUITE 100, BLUE BELL PA 19422
Gerrit Dispersyn	officer: Chief Development Officer	257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
John A Barrett	officer: Chief Development Officer	257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Geert Cauwenbergh	director, officer: President and CEO	1 STULTS DRIVE, PLAINSBORO NJ 08536
Alexey Eliseev	officer: Chief Business Officer	257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Jonathan E Freeman	director	257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Curtis Lockshin	director	4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
H. Paul Dorman	director	1500 WEST PARK DRIVE, SUITE 210, WESTBOROUGH MA 01581
Opko Health, Inc.	10 percent owner	4400 BISCAYNE BLVD., MIAMI FL 33137
Advanced Rna Technologies, Llc	10 percent owner	1 KENDALL SQUARE BUILDING 200, SUITE 2203, CAMBRIDGE MA 02139
Keith L Brownlie	director	777 OLD SAW MILL RIVER RD, TARRYTOWN NY 10591
Pamela Pavco	officer: Chief Development Officer	C/O RXI PHARMACEUTICALS CORPORATION, 1500 WEST PARK DRIVE, WESTBOROUGH MA 01581
Caitlin Kontulis	officer: Secretary and Controller	1500 WEST PARK DRIVE, SUITE 210, WESTBOROUGH MA 01581